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studies have shown that the interpretation of results obtained with 
NAA techniques should be carried out with the greatest caution. For 
good laboratory performance, a test should be monitored by negative 
and positive controls for each step of the procedure in every run. In 
order to avoid false-positive results through contamination with 
aniplicons, the application of an anti-contamination system is obliga- 
tory Inhibition of the aniplification reaction should be nionitored by 
the use of an interndl control in each sample. Even with these 
measures, cross-contamination between samples occurs every now 
and then, or target DNA/RNA may be lost during pretreatment 
procedures. To obtain optimal performance, training of laboratory 
\taff nceds attention and autoniation of procedure\ should be 
introduced whenever possible. International availahle standards are 
required to estiiiidte the detection level ofa  method and the variation 
between laboratories. Regularly organized performance studies will 
help to improve the quality of NAA-based tests for application in the 
clinical laboratory. 
Is1951 Viral central nervous system (CNS) infections- 
diagnostic strategies 
S. Read. A!Jirropatltolo,qy Ltd., Inst. of Rcsrarch and Develop. 
Birni inglirharn , IIK 
P C R  assays have been evaluated in the diagnosis of suspected viral 
CNS disease in two series ofpatients. The initial ainis were to identify 
which virures cmse CNS infection in the UK, to design assays with 
good utility for routine use, and to assess the diagnostic accuracy of 
PCR of cerebrospinal fluid (CSF). 
It? r/ie+rsr serifs, 2 . 3 3  CSF specimens iuere rested. I ' i d  nircleir arid u m  
dcrccrcd i n  6.6"b utrd j w r  sers of primers detected 9406 .f the p~xitii,e 
spcciirrcws. .4 puricrrt irifli '1 positiw r i ~ ~ u l t  u~as 88 rimrs as likcly to h n i v  t i  
drfirrirr diqno.~is 4 vird it!l;.rrion uf the CNS as a parierzr with a rzrpriiv 
PCR r w r l r .  -4 r r g a t i i v  PCR r d f  could br uscd with niod~ratr  confiderice 
ro nrlc otrr a dia'qtiosii ~$iirol  ir!fcrtion $the CNS. 
The  second series of 10x3 CSF specimens was tested with P C R  
assays with higher molecular sensitivities and improved utility for 
routine use. Multiplex assays were developed, one detecting the niost 
frequent c~iuses of viral meningitis and encephalitis in the UK (HSV- 
1, HSV-2, VZV and enteroviruses), and another detecting viruses 
that cause CNS disease in the immunosuppressed (CMV, EUV and 
HHV6). Viral nucleic acid was detected in 8.4% of the specimens 
and, compared to the accepted relative incidence of viral etiologies 
of aseptic mcningitis, HSV-2 detection was more frequent. 
We have concluded that. with appropriate multiplex assays, P C R  
can be routinely and economically applied as the first-line laboratory 
test for the diagnosis of viral infections of the CNS and that thls is 
now the 'gold standard' approach to this problem. 
Chronic hepatitis: new approaches in 
diagnosis and treatment 
(s1981 Molecular antiviral strategies 
E von Weizsaecker. h fed .  Lhiu k-liriik, Freilncg, Ccrniauy 
As a leading cause of liver cirrhosis and hepatocellular carcinoma, 
chronic viral hepatitis poses a major healthcdre problem. The vast 
majority of all cases of chronic viral hepatitis are due to hepatitis B 
or C virus infection. Whilr 5ensitive diagnostic tests are available for 
both viral infections, therapy remains unsatisfactory. In the search for 
new therapeutic options, several genetic antiviral Strategies are 
currently being explored. Apart froin DNA v.iccination, 'in attractive 
concept IS blocking viral gene expression or function within the cell 
('intracellular immunization'). Antisense nucleic acids are desibmed to 
specifically bind to RNA,  rerulting in the formation of l1NA-IINA 
(antitense DNA) or RNA-KNA (antisense KNA) hybrids with an 
arrest of K N A  replication, reverse transcription or messenger KNA 
translation. Antisense effects can be potentiated by degradation of 
R N A  in KNA-DNA hybrids by cellular RNases. Ribozymes 
('ribonucleic acid enzynies') are small ILNA molecules that catalyze 
the sequence-specific cleavdge of a given tat-get KNA. liiterferiiig 
peptides or proteins, including single-chain or  whole non-secrcted 
antibodies, are aimed at the specific interference with the assenihly 
or  function of viral structural or non-ctructural protenic. While cell- 
culture experiments have yielded encouraging rewlts, experimental 
studies in animal iiiodels will be needed to fully assess the ther'ipeutic 
potential of these molecular antiviral strategic.c.) 
m] DNA immunization for HBV infection 
M.L. Michel. Pmtenr Instirure, Ih'SERhl 
DNA vaccines induce immune responses against antigens synthesized 
in vivo after direct introduction of the DNA's encoding sequcnces. 
This unique approach to ~niniunizdtion may overcome the deficits of 
traditional antigen-based approaches and provide safe and effective 
prophylactic and therapeutic vaccines. 
Systemic itnniunization of mice by Intramuscular injection of 
plasniid DNA expressing hepatitis B virus (HBV) envelope proteinc 
and HUV surface antigen (HBsAg) inducec rapid, strong and 
sustained huinoral and cell-mediated ininiune responw. Antibod~es, 
which are initially of the IgM and then of the Ig<; irotype 
(predominantly lgG:,J, recognize several of the U-cell cpitopes 
present on the S, preS2 or preSl domains of the envelope protcins. 
High titers of anti-HL3s are present by 1-8 weeks md persist for at 
least 17 nionths after a single DNA injection, although they c m  be 
boosted 1 0-fold by a second Injection of DNA, or sonicwhat Ic\s by 
injection of a recombinant HUsAg protein. A strong cellular iniiiiune 
response IS induced hy the l>NA-baced ininiiinization, with hlgh 
levels of CTL and CTL precursors being detected by 1 week and 
being maintained for wveral months. A DNA vaccines also acts d\ its 
own adjuvant, owing to  the presence of bacterial iiiimurioctiiiiu1ato1-y 
CpG iriotik Such seqiiences present in the plasnnd backbone 
promote a Thl-like pattern of cytokine production dominated by 
IL-32 and 1FN-y with little tecretion of Th2  cytokiiirr. 
Ininiunization of mice that are transgenic for the human HLA- 
A2.1 molecule and knock-out for inurine M H C  class 1 moleculec 
with DNA-encoding HBsAg shows that epitopes presented .ifter in 
vivo procesing in HLA-A2 T g  mice are very siniila to those 
generated in huiiians during HBV infection. 
Owing to the endogenous synthesis of antigen, processing into 
relevant epitopes and the induction of CDX CTLs, DNA vciccines 
may be useful to treat individuals chronically infected with HUV As 
a model to study the possibility of inducing an immune response in 
HBV chronic carriers that could control the infection, we uscd trans- 
genic mice (Tg) th'it constitutively express the HBsAg in the liver 
only. These T g  inice secrete large amounts of HBsAg into the seruni 
without antibody production and they \how no liver pathology. 
Using a plasmid DNA encoding the s n i d  and the niiddlc HBV 
envelope protein, we were able to gencrate anti-HBs antibodies III 
these transgenic mice, which in turn induce the clearance of  circu- 
lating HBsAg. This elimination, which was persistent, war also 
correlated with d decrease or  a disappearance of the HBV messenger 
R N A  from the liver. Experinients involving the transfer of frac- 
tionated HbsAg-primed spleen cells obt.iined from DN A-iniiiiunized 
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mice into Tg mice showed that both CD4’ and CD8+ T-cells were 
able to control the transgene expression even in the absence of 
antibody production. Results from HBsAg-Tg mice that are knock- 
out for the IFN-( receptor gene indicate that the regulation of the 
HBV envelope messenger RNA was mediated by type 1 cytokines 
produced by the activated T-lymphocytes. 
These results point to the possibility of designing more effective 
methods for the prevention and the treatment of HBV infections. 
1- Hepatitis B and &a chance for therapeutic 
peptide T-cell vaccination? 
G.K. Pape. Medical Clinic II, Klinikum Grosshadern and Institutefor 
Immunolofy, Ludwig-Maxirnilians- University, Munich, Germany 
Understanding both the immune response by which the host defends 
against hepatitis B and C virus and the mechanisms by which the 
immune response can be manipulated or modulated is a prerequisite 
for the design of novel strategies for the treatment of these viral 
diseases. With regard to both aspects we have made tremendous 
progress in recent years: T-lymphocytes are the players in the defense 
against infection. A vigorous, polyclonal, niultispecific CD8’ and 
CD4+ T-cell response is associated with viral clearance in hepatitis B 
and C. Furthermore, the virus-specific T-cell response is not only 
decisive in clearing the virus but has to be maintained to control viral 
infection. For HCV infection it has been shown that loss of the T- 
cell response leads to recurrence of HCV In patients with chronic 
viral hepatitis, the virus-specific T-cell response is absent or weak and 
more focused, a state which is called non-reactivity or ‘tolerance’ of 
T-cells. T-cells can be induced or activated by virus-specific peptides. 
Thus a principal basis of novel treatment strategies in viral hepatitis 
is the delivery and presentation of virus-specific peptides to T-cells 
of chronically infected patients in order to break their T-cell tolerance 
and successfully control the virus. 
Helicobacter pylori 
Sequencing of the Helicobacter pylori genome: 
application for knowledge of pathogenesis 
A. Labigne, P. Jenks. Insritut Pasteur, Paris, France 
In July 1997, Helicobacterpylori became the tenth bacteria to have its 
entire genome sequenced. The sequence (1.6 megabases) was pub- 
lished by The Institute for Genomic Research (TIGR), and 
represents a major resource for understanding how this organism 
colonizes the human stomach and causes gastroduodenal disease. 
Examination of the genome sequence of H. pylori has already 
identified new putative virulence factors, unraveled basic metabolic 
pathways, and provided further information on genetic organization 
and the regulation of gene expression. In the future, the genome of 
this single isolate will greatly facilitate research into specific areas of 
this bacterium’s biology, such as iron regulation, the role of recently 
identified adhesins, and the relative importance of antigenic variation 
of LPS in vivo it will also enable researchers to adopt a more global 
approach to the study of H. pylori and will allow: (1) examination of 
the genetic diversity of clinical isolates (gene polymorphism and 
diversity in genomic complement and organization); (2) charac- 
terization of differential gene expression of clinical isolates in relation 
to in vitro and in vivo conditions; (3) identification of genes essential 
for colonization of the gastric mucosa. 
Sequencing of the Helicobacter pylori genome: 
application for defining new therapeutics 
T.J. Trust. Astra Research Center Boston, MA, USA 
Knowledge of the complete genomic sequence of pathogenic 
bacteria is creating unprecedented opportunities to understand the 
pathogenesis of infectious disease and to discover new therapeutics, 
both drugs and vaccines. A genome-based strategy facilitates the 
escient identification of all antigens of a pathogen, as well as the 
rapid advanced selection of novel lethal targets not used by today’s 
antibiotics, thus providing the opportunity to identify novel classes 
of antibacterials. Helicobacter pylori is the first bacterial pathogen for 
which the complete -1.65 megabase nucleotide genome sequence of 
two isolates has been determined. O f  the -1500 H. pylori genes, 
approximately 58% have been assigned predicted function based on 
sequence similarity to a gene product of demonstrated function, 
while another 18% have homologues of unknown identity. The 
remainder have no currently identified homologues in the public data 
bases and are currently H. pylori specific. A small number of strain- 
specific genes are also present. Comparison of the two genome 
sequences has provided new insight on genomic evolution in the 
species. A number of a number of factors, including strain-specific 
genes, which could influence the clinical outcome of H. pylori 
infections have been revealed. The comparison has also identified a 
‘common set’ of H. pylori genes, which includes both novel potential 
vaccine antigens and possible drug targets for the development ofnew 
anti-H. pylori therapeutics. 
Host response to Helicobacter pylori infection: 
the ThlITh2 balance 
M.M.D. Elios, A. Amedei, G. Del Prete. Internal Medicine, CIRHel: 
University of Floreuce, Florence, Italy 
H. pylori infection represents the major cause of gastroduodenal 
disease, but only a minority of infected patients develop, throughout 
their life, gastroduodenal pathologies, like peptic ulcer, gastric cancer 
or B-cell lymphoma. The type of host immune response against H. 
pylori seems to be crucial for the outcome of the infection. 
An experimental model has been developed to investigate at clonal 
level the gastric T-cell response to H. pylori occurring in infected 
patients with uncomplicated chronic gastritis, peptic ulcer or gastric 
low-grade lyniphoma (MALToma). 
A predominant H. pylori-specific T h l  response, characterized by 
high IFN-gamma, IL-12 and TNF-alpha production, was found in 
the gastric antrum of patients with peptic ulcer. In uncomplicated 
chronic gastritis, most gastric H. pylori-specific T-cells showed com- 
bined secretion ofboth Thl -  and Th2-type cytokines (Tho profile). 
Likewise, Tho was the predominant cytokine profile of T-cells 
derived from gastric MALToma. Interestingly, however, gastric T- 
cells from MALToma, but not T-cells from chronic gastritis with or 
without ulcer, exhibited abnormal help for autologous B-cell proli- 
feration and reduced perforin- and Fas-Fas ligand-mediated killing 
of B-cells. 
These data suggest that host gastric immune response to H .  pylori 
can influence the clinical picture and that peptic ulcer may be an 
immunopathologic consequence of a T h l  -polarized response to 
some H. pylori antigens, whereas exhaustive and deregulated H. 
pylori-induced T-cell-dependent B-cell activation may support the 
onset of low-grade B-cell lymphoma. 
